# Anti-FLT3 CAR-T Cell (TAA05 Cell Injection) in the Treatment of Relapsed / Refractory Acute Myeloid Leukemia

> **NCT05445011** · PHASE1 · RECRUITING · sponsor: **Union Hospital, Tongji Medical College, Huazhong University of Science and Technology** · enrollment: 12 (estimated)

## Conditions studied

- Acute Myeloid Leukemia

## Interventions

- **DRUG:** Fludarabine + Cyclophosphamide + TAA05 Cell Injection

## Key facts

- **NCT ID:** NCT05445011
- **Lead sponsor:** Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-06-14
- **Primary completion:** 2025-06-14
- **Final completion:** 2027-06-14
- **Target enrollment:** 12 (ESTIMATED)
- **Last updated:** 2022-07-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05445011

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05445011, "Anti-FLT3 CAR-T Cell (TAA05 Cell Injection) in the Treatment of Relapsed / Refractory Acute Myeloid Leukemia". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT05445011. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*